Inventor · disambiguated record
James J. Doherty
Also filed as: DOHERTY JAMES · DOHERTY JAMES J · DOHERTY JR JAMES J
4 granted patents·26 pending applications·32 citations·filing 2002–2025
74Inventor score
Top patents by PatentIndex Score
30 records- 0197US11236121B2Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2017·Granted Feb 1, 2022·23 cites·5 claims
- 0295US11884696B2Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·4 cites·19 claims
- 0384US2025304615A1Crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0481US12358942B2Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·4 claims
- 0579US2025339447A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0675US2025268916A1Method of treating cns disorders with neurosteroids and gabaergic compoundsSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0773US2024353415A1Method of screening compounds for treating cns disordersSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0872US2023201224A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0972US2022323462A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1070US2025387414A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1167US7375136B2pH-dependent NMDA receptor antagonistsUNIV EMORY·Filed 2002·Granted May 20, 2008·5 cites·8 claims
- 1266US2023116196A1Method of treating cns disorders with neurosteroids and gabaergic compoundsSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1366US2023218638A1Neuroactive compounds and methods of use thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1461US2022110949A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1559US2020113917A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1659US2021369734A1Compounds and methods of their useSAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1758US2021338692A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1858US2025319105A1Neuroactive steroid for the treatment of alzheimer's diseaseSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1958US2025295674A1Neuroactive steroids for treatment of cns-related disordersSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2057US2024216396A1Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating femaleSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2156US2020341000A1Method of screening compounds for treating cns disordersSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2254US2024245711A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorderSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2354US2024252514A1Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's diseaseSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2454US2024216395A119-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depressionSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2552US2009023791A1PH-dependent NMDA receptor antagonistsUNIV EMORY·Filed 2008·Application pending·0 cites
- 2651US2021228596A1Method of treating cns disorders with neurosteroids and gabaergic compoundsSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2750US2023018765A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2850US2020306262A1Compounds and methods of their useSAGE THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2944US2016022701A1Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3036US2017304321A1Neuroactive compounds and methods of use thereofSAGE THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James J. Doherty files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →